TD Cowen Maintains Buy on Roivant Sciences, Raises Price Target to $41
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
TD Cowen analyst Yaron Werber maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $38 to $41.
TD Cowen analyst Yaron Werber maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $38 to $41.